While the BBB is often seen as an obstacle, it can also be leveraged to enhance treatment specificity. By designing drugs that are activated only upon crossing the BBB or targeting specific transport mechanisms, therapies can be made more selective for CNS tumors, potentially reducing systemic side effects.
